Silver Book reference

A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

4 Matching Facts

Search matching Facts:
No results to display
    • Use of shingles vaccines significantly reduced disease burden
      Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.  
    • Shingles vaccine reduces incidence by >50%
      Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.  
    • Shingles pain occurs in ~50% of cases in older adults
      Complications of shingles—including postherpetic neuralgia (PHN)—occur in almost 50 percent of older persons with the disease.  
    • Postherpetic neuralgia in shingles
      Complications, including postherpetic neuralgia (PHN) occur in ~50% of older persons with shingles.